Traditional methods could only qualitatively detect the presence of the Y chromosome, failing to distinguish between male-male twins and male-female twins. They also lacked the capability to identify residual male cfDNA after fetal reduction procedures. Zentrogene’s NGS-based technology achieves three breakthroughs:
- Fetal Signal Assessment: Utilizes whole-genome SNP scanning to confirm fetal signal presence, precisely quantify fetal fraction, and determine the number of fetal signals.
- Contamination Identification: Differentiates between false signals (e.g., contamination-derived Y chromosome fragments) and true fetal signals.
- Twin Pregnancy Precision Analysis: Independently analyzes X and Y chromosome fragments to accurately distinguish male-female twins from male-male twins.
As a pioneer in Hong Kong’s genetic testing field, Zentrogene has established a global technology matrix covering pre-pregnancy, prenatal, and oncology applications through its integrated Sanger sequencing and NGS platforms. This NGS breakthrough underscores its ‘Technology-Driven Globalization’ strategy, leveraging Hong Kong’s expertise to deliver precision medical solutions worldwide. Zentrogene continues to advance genetic technology, safeguarding every family’s hopes with scientific rigor.
For details, visit:
https://www.zentrogene.com/
https://www.zentrogene.com.hk/
Official Cooperation Contacts:
Telephone: +86 18051865085 (WeChat same number)
Telegram: +855 99990026
Facebook: Zentrogene
Hashtag: #Zentrogene
The issuer is solely responsible for the content of this announcement.
Follow Arabian Post
Select Arabian Post as your preferred source on Google and MSN News for trusted business news and Arab politics and updates.
